Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue.

The inhibition mechanism of matrix metalloproteinase 2 (MMP2) by the selective inhibitor (4-phenoxyphenylsulfonyl)methylthiirane (SB-3CT) and its oxirane analogue is investigated computationally. The inhibition mechanism involves C-H deprotonation with concomitant opening of the three-membered heterocycle. SB-3CT was docked into the active site of MMP2, followed by molecular dynamics simulation to prepare the complex for combined quantum mechanics and molecular mechanics (QM/MM) calculations. QM/MM calculations with B3LYP/6-311+G(d,p) for the QM part and the AMBER force field for the MM part were used to examine the reaction of these two inhibitors in the active site of MMP2. The calculations show that the reaction barrier for transformation of SB-3CT is 1.6 kcal/mol lower than its oxirane analogue, and the ring-opening reaction energy of SB-3CT is 8.0 kcal/mol more exothermic than that of its oxirane analogue. Calculations also show that protonation of the ring-opened product by water is thermodynamically much more favorable for the alkoxide obtained from the oxirane than for the thiolate obtained from the thiirane. A six-step partial charge fitting procedure is introduced for the QM/MM calculations to update atomic partial charges of the quantum mechanics region and to ensure consistent electrostatic energies for reactants, transition states, and products.

[1]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[2]  Feliu Maseras,et al.  IMOMM: A new integrated ab initio + molecular mechanics geometry optimization scheme of equilibrium structures and transition states , 1995, J. Comput. Chem..

[3]  Kenneth M. Merz,et al.  Force Field Design for Metalloproteins , 1991 .

[4]  G. Smith,et al.  Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors , 2002, Molecular and Cellular Endocrinology.

[5]  Akash Khandelwal,et al.  QM/MM linear response method distinguishes ligand affinities for closely related metalloproteins , 2007, Proteins.

[6]  Thom Vreven,et al.  Model studies of the structures, reacitivities, and reaction mechanisms of metalloenzymes , 2001, IBM J. Res. Dev..

[7]  K. Morokuma,et al.  ONIOM: A Multilayered Integrated MO + MM Method for Geometry Optimizations and Single Point Energy Predictions. A Test for Diels−Alder Reactions and Pt(P(t-Bu)3)2 + H2 Oxidative Addition , 1996 .

[8]  L. Liotta,et al.  Partial purification and characterization of a neutral protease which cleaves type IV collagen. , 1981, Biochemistry.

[9]  Thom Vreven,et al.  Transition States in a Protein Environment - ONIOM QM:MM Modeling of Isopenicillin N Synthesis. , 2009, Journal of chemical theory and computation.

[10]  S. Meroueh,et al.  Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. , 2005, Organic letters.

[11]  P. Kollman,et al.  Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .

[12]  Robert Huber,et al.  Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. , 2007, Journal of molecular biology.

[13]  Tom L. Blundell,et al.  X-RAY STRUCTURE OF GELATINASE A CATALYTIC DOMAIN COMPLEXED WITH A HYDROXAMATE INHIBITOR , 1999 .

[14]  S. Meroueh,et al.  Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. , 2007, Journal of the American Chemical Society.

[15]  K. Morokuma,et al.  Computational insights into the mechanism of radical generation in B12-dependent methylmalonyl-CoA mutase. , 2006, Journal of the American Chemical Society.

[16]  Thom Vreven,et al.  Geometry optimization with QM/MM, ONIOM, and other combined methods. I. Microiterations and constraints , 2003, J. Comput. Chem..

[17]  S. Mobashery,et al.  Conformational analyses of thiirane-based gelatinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[18]  R. Schulz,et al.  Pimecrolimus: a review , 2022 .

[19]  M. Frisch,et al.  CASSCF calculations for photoinduced processes in large molecules: Choosing when to use the RASSCF, ONIOM and MMVB approximations , 2007 .

[20]  M. Bernardo,et al.  Potent Mechanism-based Inhibitors for Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.

[21]  K. Morokuma,et al.  On the application of the IMOMO (integrated molecular orbital + molecular orbital) method , 2000 .

[22]  F. Diederich,et al.  Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. , 2006, Angewandte Chemie.

[23]  Keiji Morokuma,et al.  The IMOMO method: Integration of different levels of molecular orbital approximations for geometry optimization of large systems: Test for n‐butane conformation and SN2 reaction: RCl+Cl− , 1996 .

[24]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[25]  C. Janson,et al.  Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.

[26]  Peng Tao,et al.  DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. , 2009, Organic Letters.

[27]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[28]  S. Mobashery,et al.  Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.

[29]  Yunbo Shi,et al.  Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development. , 2007, Pharmacology & therapeutics.

[30]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[31]  R. Fridman,et al.  Active Site Ring‐Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases , 2009, Chemical biology & drug design.

[32]  A. Noël,et al.  Matrix metalloproteinases at cancer tumor-host interface. , 2008, Seminars in cell & developmental biology.

[33]  Ping-Heng Tan,et al.  Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain , 2008, Nature Medicine.

[34]  F. Luft Matrix metalloproteinases and their regulators are cardiovascular therapeutic targets , 2004, Journal of Molecular Medicine.

[35]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[36]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[37]  S. Meroueh,et al.  Structural Basis for Potent Slow Binding Inhibition of Human Matrix Metalloproteinase-2 (MMP-2)* , 2003, Journal of Biological Chemistry.

[38]  Thom Vreven,et al.  Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM. , 2006, Journal of chemical theory and computation.

[39]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[40]  K. Morokuma,et al.  A NEW ONIOM IMPLEMENTATION IN GAUSSIAN98. PART I. THE CALCULATION OF ENERGIES, GRADIENTS, VIBRATIONAL FREQUENCIES AND ELECTRIC FIELD DERIVATIVES , 1999 .

[41]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.

[42]  W. Stallings,et al.  Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. , 2002, Biochimica et biophysica acta.

[43]  S. Janssens,et al.  What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? , 2006, Cardiovascular research.

[44]  L. Kotra,et al.  Potent and Selective Mechanism-Based Inhibition of Gelatinases , 2000 .

[45]  Satya P. Gupta,et al.  Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. , 2007, Chemical reviews.

[46]  Katie M. Reindl,et al.  Quantitative characterization of binding of small molecules to extracellular matrix. , 2006, Journal of biochemical and biophysical methods.

[47]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  D. Suárez,et al.  Molecular dynamics simulations of the active matrix metalloproteinase‐2: Positioning of the N‐terminal fragment and binding of a small peptide substrate , 2008, Proteins.

[49]  Thom Vreven,et al.  Geometry optimization with QM/MM methods II: Explicit quadratic coupling , 2006 .

[50]  G. Homandberg,et al.  Hyaluronan enhances cartilage repair through low grade tissue remodeling involving cytokines and matrix metalloproteinases , 2004, Inflammation Research.

[51]  K. Morokuma,et al.  Is the protein surrounding the active site critical for hydrogen peroxide reduction by selenoprotein glutathione peroxidase? An ONIOM study. , 2006, The journal of physical chemistry. B.

[52]  V. Lukacova,et al.  A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. , 2005, Journal of medicinal chemistry.

[53]  Y. Itoh,et al.  Matrix metalloproteinases in cancer. , 2002, Essays in biochemistry.

[54]  E. Furth,et al.  Induction of matrix metalloproteinases and collagenolysis in chick embryonic membranes before hatching. , 1999, Biology of reproduction.

[55]  Todd J. A. Ewing,et al.  Critical evaluation of search algorithms for automated molecular docking and database screening , 1997, J. Comput. Chem..

[56]  Viera Lukacova,et al.  Binding of Matrix Metalloproteinase Inhibitors to Extracellular Matrix: 3D‐QSAR Analysis , 2008, Chemical biology & drug design.

[57]  Akash Khandelwal,et al.  Improved estimation of ligand–macromolecule binding affinities by linear response approach using a combination of multi-mode MD simulation and QM/MM methods , 2007, J. Comput. Aided Mol. Des..

[58]  Chi-Hsien Liu,et al.  Characterization of matrix metalloproteinase expressed by human embryonic kidney cells , 2006, Biotechnology Letters.

[59]  Soumyendu Raha,et al.  Similarity of Binding Sites of Human Matrix Metalloproteinases*[boxs] , 2004, Journal of Biological Chemistry.